Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib maintenance and long-term extension study in Crohn's disease
NL-OMON59078Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in Crohn's disease (4 arms), sponsored by AbbVie Inc. Started Jul 2017; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59078.